{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:00:22Z","timestamp":1761181222051,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jbspin.2020.02.009","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T03:15:42Z","timestamp":1583723742000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA)"],"prefix":"10.1016","volume":"87","author":[{"given":"Jasvinder A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Tornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2020.02.009_bib0290","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0295","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncprheum0047","article-title":"Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis","volume":"1","author":"Muller-Ladner","year":"2005","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0300","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","article-title":"Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases","volume":"9","author":"Feldmann","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0305","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0310","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0320","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"355","author":"Scott","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0325","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","article-title":"Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis","volume":"5","author":"Taylor","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0330","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","article-title":"New drugs for rheumatoid arthritis","volume":"350","author":"Olsen","year":"2004","journal-title":"N Engl J Med"},{"author":"Pharma Intelligence","key":"10.1016\/j.jbspin.2020.02.009_bib0335"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0340","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0345","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.clinthera.2015.04.012","article-title":"Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis","volume":"37","author":"Baser","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0350","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.clinthera.2017.06.009","article-title":"Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany","volume":"39","author":"Li","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0360","article-title":"Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naive patients with rheumatoid arthritis","author":"Lauper","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0365","doi-asserted-by":"crossref","DOI":"10.1002\/art.41031","article-title":"Comparative effectiveness of certolizumab pegol, abatacept and biosimilar infliximab in patients with rheumatoid arthritis treated in routine care. Observational data from the Danish DANBIO registry emulating a randomized trial","author":"Gron","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0370","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40744-019-0149-3","article-title":"Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry","volume":"6","author":"Harrold","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0375","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0380","first-page":"507","article-title":"Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs","volume":"5","author":"Harrold","year":"2018","journal-title":"Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis. Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0385","doi-asserted-by":"crossref","first-page":"e021447","DOI":"10.1136\/bmjopen-2017-021447","article-title":"Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases","volume":"8","author":"Silvagni","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0390","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0395","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2017.10.003","article-title":"A Bayesian model that jointly considers comparative effectiveness research and patients\u2019 preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations","volume":"93","author":"Hazlewood","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0400","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2147\/PPA.S66849","article-title":"Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis","volume":"8","author":"Zwikker","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0405","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1532-5415.1999.tb04575.x","article-title":"Medication adherence in rheumatoid arthritis patients: older is wiser","volume":"47","author":"Park","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0410","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/1756-185X.13660","article-title":"Rheumatologists\u2019 insight into medication adherence in patients with rheumatoid arthritis: A qualitative study","volume":"22","author":"Heidari","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0415","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2017.12.010","article-title":"Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis?. A systematic review","volume":"48","author":"Heidari","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0420","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/08870446.2016.1139111","article-title":"\u2019The lesser of two evils.\u2019 - views of persons with rheumatoid arthritis on medication adherence: a qualitative study","volume":"31","author":"Brandstetter","year":"2016","journal-title":"Psychol Health"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0425","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.5888\/pcd15.180218","article-title":"Self-Efficacy and Adherence Behaviors in Rheumatoid Arthritis Patients","volume":"15","author":"Oshotse","year":"2018","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0430","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1080\/09638288.2016.1212111","article-title":"A longitudinal, qualitative study exploring sustained adherence to a hand exercise programme for rheumatoid arthritis evaluated in the SARAH trial","volume":"39","author":"Nichols","year":"2017","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0435","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2147\/PPA.S174672","article-title":"Exploring strategies to support medication adherence in patients with inflammatory arthritis: a patient-oriented qualitative study using an interactive focus grou*p activity","volume":"12","author":"Rai","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0440","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-018-1732-7","article-title":"I do not want to suppress the natural process of inflammation: new insights on factors associated with non-adherence in rheumatoid arthritis","volume":"20","author":"Ritschl","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0445","doi-asserted-by":"crossref","first-page":"e114350","DOI":"10.1371\/journal.pone.0114350","article-title":"Fears and beliefs in rheumatoid arthritis and spondyloarthritis: a qualitative study","volume":"9","author":"Berenbaum","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0450","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/acr.23541","article-title":"Experience and Context Shape Patient and Clinician Goals For Treatment of Rheumatoid Arthritis: A Qualitative Study","volume":"70","author":"Barton","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0455","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002164","article-title":"A qualitative interview study: patient accounts of medication use in early rheumatoid arthritis from symptom onset to early postdiagnosis","volume":"3","author":"Townsend","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0460","first-page":"1294","volume":"54","author":"Hart","year":"2015","journal-title":"Young people's decisions about biologic therapies: who influences them and how?. Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0465","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/jme.2007.023705","article-title":"Information and participation in decision-making about treatment: a qualitative study of the perceptions and preferences of patients with rheumatoid arthritis","volume":"34","author":"Schildmann","year":"2008","journal-title":"J Med Ethics"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0470","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/ard.2003.019422","article-title":"Patient preferences for treatment of rheumatoid arthritis","volume":"63","author":"Fraenkel","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0475","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-019-04609-y","article-title":"Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy","author":"Raghunath","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0480","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/msc.1367","article-title":"Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients\u2019 perceptions and needs","volume":"17","author":"Hewlett","year":"2019","journal-title":"Musculoskeletal Care"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0485","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0490","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0495","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/014572170002600211","article-title":"Nominal group technique: a process for identifying diabetes self-care issues among patients and caregivers","volume":"26","author":"Miller","year":"2000","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0500","first-page":"13","article-title":"A fresh approach to group goal setting","volume":"2","author":"Hegger","year":"1986","journal-title":"The three-way rotation nomimal group technique. J Nurs Staff Dev"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0505","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/fampra\/10.1.76","article-title":"The nominal group technique: a research tool for general practice?","volume":"10","author":"Gallagher","year":"1993","journal-title":"Family Practice"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0510","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.evalprogplan.2009.11.002","article-title":"Use of the Nominal Group Technique (NGT) to understand the perceptions of the healthiness of foods associated with African Americans","volume":"33","author":"Jefferson","year":"2010","journal-title":"Eval Program Plann"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0515","first-page":"974964","article-title":"A Patient-Based Needs Assessment for Living Well with Parkinson Disease: Implementation via Nominal Group Technique","volume":"2013","author":"Kleiner-Fisman","year":"2013","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0520","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/146642409611600303","article-title":"Identifying problems in community health promotion: an illustration of the Nominal Group Technique in AIDS education","volume":"116","author":"MacLachlan","year":"1996","journal-title":"J R Soc Health"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0525","first-page":"859","article-title":"Outcome indicators in palliative care--how to assess quality and success. Focus group and nominal group technique in Germany","volume":"18","author":"Pastrana","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0530","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jhm.1900","article-title":"Nominal group technique: a brainstorming tool for identifying areas to improve pain management in hospitalized patients","volume":"7","author":"Pena","year":"2012","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0535","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1467-842X.1997.tb01695.x","article-title":"Consulting about priorities for the NHMRC National Breast Cancer Centre: how good is the nominal group technique","volume":"21","author":"Redman","year":"1997","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0540","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0545","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0550","first-page":"809","article-title":"Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients","volume":"23","author":"Desai","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0555","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0560","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0565","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jprot.2016.09.009","article-title":"Quantitative proteomics reveals ecological fitness cost of multi-herbicide resistant barnyardgrass (Echinochloa crus-galli L.)","volume":"150","author":"Yang","year":"2017","journal-title":"J Proteomics"},{"key":"10.1016\/j.jbspin.2020.02.009_bib0570","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40801-016-0093-2","article-title":"Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study","volume":"3","author":"Gu","year":"2016","journal-title":"Drugs Real World Outcomes"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20300361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:25:47Z","timestamp":1761150347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X20300361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1297319X20300361"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.02.009","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA)","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}